hydrazine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberch, J; Anglada-Huguet, M; Giralt, A; Martín, ED; Xifró, X; Zamora-Moratalla, A | 1 |
| Hussar, DA | 1 |
| Allan, BM; Baird, PA; Diewold, PA; Hansen, S; Perry, TL; Thomas, SM; Wright, JM | 1 |
| Dill, RE; Dorris, RL; Phillips-Thonnard, I | 1 |
| Birkmayer, W | 1 |
| Candelise, L; Faglioni, P; Spinnler, H; Vignolo, LA | 1 |
3 trial(s) available for hydrazine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
A double-blind clinical trial of isoniazid in Huntington disease.
Topics: Adult; Aged; Amino Acids; Ataxia; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Huntington Disease; Hydrazines; Isoniazid; Male; Middle Aged | 1982 |
[10 years of L-DOPA therapy of Parkinson's syndrome].
Topics: Administration, Oral; Amphetamine; Animals; Brain Chemistry; Catecholamines; Clinical Trials as Topic; Cognition Disorders; Constipation; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Feeding and Eating Disorders; Hallucinations; Humans; Huntington Disease; Hydrazines; Hypertension; Infusions, Parenteral; Injections, Intravenous; Monoamine Oxidase Inhibitors; Movement Disorders; Nausea; Norepinephrine; Parkinson Disease; Serotonin; Stimulation, Chemical; Time Factors; Tremor; Vomiting | 1971 |
Letter: Treatment of Huntington's chorea.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Clinical Trials as Topic; Diazepam; Dihydroxyphenylalanine; Drug Therapy, Combination; Haloperidol; Humans; Huntington Disease; Hydrazines; Reserpine | 1973 |
3 other study(ies) available for hydrazine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Huntington Disease; Hydrazines; Male; Memory Disorders; Mice; Mice, Inbred CBA; Mice, Transgenic; Motor Skills Disorders; Oxazepines; Receptors, Prostaglandin E, EP1 Subtype | 2014 |
New drugs 09, part 2.
Topics: Adrenergic Uptake Inhibitors; Angioedemas, Hereditary; Benzoates; Carrier Proteins; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluprednisolone; Humans; Huntington Disease; Hydrazines; Keratitis; Nurse's Role; Ophthalmologic Surgical Procedures; Pain, Postoperative; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Pyridines; Receptors, Fc; Recombinant Fusion Proteins; Tetrabenazine; Thrombopoietin; Uveitis | 2009 |
A pharmacologic model of Huntington's chorea.
Topics: Animals; Carbachol; Catheterization; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Huntington Disease; Hydrazines; Levodopa; Male; Phentolamine; Rats; Trifluoperazine; Tyramine | 1976 |